Clinical Trials - October 17, 2023
New results from Hansa Biopharma’s Imlifidase study
The company has announced results from an extended pooled analysis using data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase. The results showed sustained positive outcomes out to 5 years in the majority of highly sensitized patients who received an imlifidase-enabled kidney […]
Business - October 11, 2023
Novo Nordisk will stop the kidney outcomes trial FLOW
The company has announced the decision to stop the once-weekly injectable semaglutide kidney outcomes trial FLOW based on interim analysis. The trial has studied the effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease. Based on a recommendation from the independent Data Monitoring […]
Clinical Trials - September 20, 2023
Guard Therapeutics reports Phase 2 results
Guard Therapeutics has announced top-line results from its AKITA study, evaluating RMC-035 for the prevention of kidney injury in open-heart surgery. Patient recruitment was prematurely stopped, and as expected the primary (short-term) endpoint, incidence of acute kidney injury (AKI) within 72 hours after surgery, was not reached, describe sthe company. “Importantly though, pre-defined secondary endpoints […]
Clinical Trials - September 5, 2023
Genmab and Seagen announce trial results
Genmab and Seagen have announced that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received TIVDAK, compared with chemotherapy alone, met its primary endpoint of overall survival (OS). An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy […]
Clinical Trials - August 23, 2023
Preliminary results from Medivir Phase 2a study
The 15th patient with advanced hepatocellular carcinoma (HCC) has been included in the company’s ongoing phase 2a study. The study evaluates safety and efficacy with the candidate drug fostrox in combination with Lenvima in patients for whom current first- or second-line treatment has proven ineffective or is not tolerable. Positive results The preliminary results from […]
Clinical Trials - August 22, 2023
First healthy volunteers dosed in Herantis’ part 2 Phase 1a study
Herantis Pharma has announced that the dosing of the healthy volunteers in part 2 of the Phase 1a clinical study has been started based on decision from the Data and Safety Monitoring Board. Top-line data of the Phase 1a clinical study is expected in Q4 2023. Thanks to its multimodal mechanism of action, Herantis’ HER-096 […]
